FeesSafety
Pluang+

Lakefront Biotherapeutics presents promising Phase 1b data on gamgertamig for autoimmune cytopenias at ASH 2026.

Market News
04 Nov 2026, 16:01 WIB
GlobeNewsWire
View Source
Bullish
Lakefront Biotherapeutics presents promising Phase 1b data on gamgertamig for autoimmune cytopenias at ASH 2026.

Lakefront Biotherapeutics announced positive initial results from Phase 1b studies of gamgertamig, a BCMAxCD3 T-cell engager, showing potential to maintain remission in autoimmune cytopenias without ongoing therapy. Data from 33 patients with immune thrombocytopenia and autoimmune hemolytic anemia showed high response rates and durable effects, with manageable safety profiles. These findings support gamgertamig’s potential as a novel treatment offering an 'immune reset' effect. Lakefront will present updated data at the 2026 American Society of Hematology meeting and hold an investor call on December 14.

Lakefront Biotherapeutics' announcement of positive Phase 1b results for gamgertamig provides context for readers. For those following the health sector, 127 of 150 US health stocks on Pluang rose today. Notable movers include Zimmer Biomet Holdings Inc (ZBH) at USD 102.00 with a +5.09% change, CVS Health Corp (CVS) at USD 86.90 down -4.93% with 91% buy order activity, and Tilray Brands Inc (TLRY) at USD 2.78 up +4.91% with 96% sell order activity. Data is as of Nov 04, 2026 20:41 WIB.

More News

Kelly Technology + Motion Recruitment named Leader by Everest Group for US IT staffing and consulting excellence

Kelly Technology + Motion Recruitment named Leader by Everest Group for US IT staffing and consulting excellence

Kelly Technology + Motion Recruitment, a division of Kelly Services, has been recognized as a Leader on Everest Group's 2026 U.S. IT Contingent Talent and Strategic Solutions PEAK Matrix® for its expertise in specialized IT staffing, consulting, and ...

Market News
Bullish
1 hour ago
Sutro Biopharma to present at multiple investor conferences in November and December 2026

Sutro Biopharma to present at multiple investor conferences in November and December 2026

Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced its participation in several investor conferences in November and December 2026, including events hosted by Stifel, Truist Securities, UBS, ...

Market News
Neutral
2 hours ago
etoro acquires Argentine fintech LB Finanzas to expand in Latin America

etoro acquires Argentine fintech LB Finanzas to expand in Latin America

etoro has agreed to acquire LB Finanzas, a leading Argentine all-in-one financial app, to strengthen its presence in Latin America's fast-growing fintech market. LB Finanzas offers integrated investing and payment solutions, catering to Argentine ret...

Company Fundamentals
Bullish
2 hours ago
JD.com to release Q3 2026 financial results on Nov 17 with a management call scheduled.

JD.com to release Q3 2026 financial results on Nov 17 with a management call scheduled.

JD.com announced it will publish its unaudited financial results for the third quarter of 2026 on November 17, before the U.S. market opens. The company's management will hold a conference call the same day to discuss the results, providing investors...

Company Fundamentals
Neutral
5 hours ago
KE Holdings to release Q3 2026 financial results on Nov 16 with a live earnings call.

KE Holdings to release Q3 2026 financial results on Nov 16 with a live earnings call.

KE Holdings Inc., a major online and offline housing platform in China, will announce its unaudited financial results for the third quarter of 2026 on November 16 before the U.S. market opens. The company will host an earnings conference call at 7:00...

Company Fundamentals
Neutral
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App